Rinvoq Receives FDA Approval for Moderate to Severe Crohn's Disease

AbbVie’s JAK inhibitor Rinvoq (upadacitinib) is now the only oral medication approved to treat moderate to severe Crohn’s disease.

Related Keywords

Minnesota ,United States ,Mayo Clinic In Rochester ,Stony Brook ,New York ,Americans ,Edwardv Loftus Jr ,Farah Monzur ,Crohn Colitis Foundation ,Drug Administration ,Stony Brook Medicine ,That Can Work Quickly ,Oral Treatment Approved ,Severe Crohn ,Disease Activity Index ,Maintenance Therapy ,Mayo Clinic ,Patient Might Benefit ,Most From ,Best Treatment ,Talk With Your ,